YM BioSciences appoints John Friedman to its Board of Directors

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
YM Bio. Com Shs	LSE:YMBA	London	Ordinary Share	CA9842381050	COM SHS NPV

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

YM Bio. Com Shs (LSE:YMBA)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more YM Bio. Com Shs Charts.

YM BioSciences appoints John Friedman to its Board of Directors MISSISSAUGA, ON, Canada, April 8 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (TSX:YM, AIM:YMBA), the cancer drug development company, today announced the appointment of Mr. John Friedman to its Board of Directors. Mr. Friedman is the Managing Partner of Easton Hunt Capital Partners of New York, whose principal investment focus is life sciences and growth capital opportunities. "Mr. Friedman's depth of experience and breadth of relationships in both the life sciences and financial industries will be an invaluable resource as we advance our late-stage portfolio of cancer drugs," said David Allan, Chairman and CEO of YM BioSciences Inc. "His appointment to the board will also help to broaden YM's presence in the US market place, which we initiated with a Cdn$19 million round of financing in December 2003. This appointment will complement YM's increasing visibility in the US resulting from the recruitment of patients into our current pivotal Phase III trial in metastatic breast cancer, and from the implementation of our previously announced intention to list on a US stock exchange." Prior to founding Easton Capital, Mr. Friedman was the founder and Managing General Partner of Security Pacific Capital Investors, a $200-million private equity fund geared towards expansion financings and recapitalizations. Mr. Friedman has also been a Managing Director and Partner at E.M. Warburg, Pincus & Co. Inc., where he spent eight and a half years. During his tenure, he was involved in Warburg's investments in Computerland, Tweeds, Babbages' and US Healthcare. Previously, Mr. Friedman was an attorney with Sullivan and Cromwell and holds a JD degree from Yale Law School and a BA degree from Yale College. He currently serves on the Boards of Conor Medsystems, Renovis, Acorda Therapeutics, Comverse Technology, Trellis Bioscience, Assistive Technology, and ModelWire, Inc., and is on the President's Council at the Cold Spring Harbor Laboratory. Mr. Friedman replaces John D. Morgan on the Company's Board of Directors, who resigned in order to accommodate the appointment of Mr. Friedman. About YM BioSciences YM BioSciences Inc. is a cancer drug development company. Its lead drug, tesmilifene, is a small molecule chemopotentiator (for taxanes and anthracyclines) that has recently been cleared by the FDA for a pivotal Phase III in metastatic breast cancer for which it had previously completed a Phase III trial with positive results. In addition to tesmilifene, the Company is developing an EGFr humanized monoclonal antibody that has completed Phase II trials and a GnRH anti-cancer vaccine also in clinical trials. YM is also supporting the preclinical development of two additional cancer products. Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. DATASOURCE: YM BioSciences Inc. CONTACT: Enquiries: James Smith, The Equicom Group Inc., Tel. +1 (416) 815-0700 x229, Email: ; YM BioSciences Inc., Tel. +1 (905) 629-9761, Fax +1 (905) 629-4959, Email:

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

YMBA YM Bio. Com Shs